Table 4.
Isolates stratified by country | IHMA number | C/T MIC (mg/L) | OprD | PBP3 (ftsI)a | WGS lactamase summary (≥72% identity; ≥80% CDS)b | Class C (intrinsic) | MLSTc |
---|---|---|---|---|---|---|---|
Kuwait | |||||||
1 | 1562186 | 8 | Frameshift, 195 AA protein | WT | PDC-109 | PDC-109 | 499 |
2 | 1562187 | >32 | No lesion | WT | PDC-119-like; OXA-4; VIM-2 | PDC-119-like | 233 |
3 | 1562188 | >32 | No lesion | WT | PDC-252-like; OXA-4; VIM-2 | PDC-252-like | 233 |
4 | 1562192 | >32 | Q158STOP | WT | PDC-119-like; OXA-4; VIM-2 | PDC-119-like | 233 |
5 | 1562196 | >32 | Frameshift, 359 AA protein | A539T | PDC-252-like; VIM-2; OXA-4 | PDC-252-like | 233 |
6 | 1562198 | >32 | No lesion | WT | PDC-35; LCR-1; VIM-2; OXA-2 | PDC-35 | 2613 |
7 | 1572968 | >32 | No lesion | WT | PDC-252-like; VIM-2 | PDC-252-like | 3482 |
8 | 1572981 | >32 | No lesion | WT | PDC-119-like; VIM-2; | PDC-119-like | 233 |
9 | 1572982 | >32 | W138STOP | WT | PDC-119-like; OXA-4-like; VIM-2 | PDC-119-like | 233 |
10 | 1572988 | >32 | Frameshift, 350 AA protein | WT | PDC-35; OXA-2; VIM-6; OXA-10 | PDC-35 | 2613 |
11 | 1607795 | 8 | No lesion | WT | PDC-30 | PDC-30 | 671 |
12 | 1607809 | >32 | Disrupted by insertion | WT | PDC-119-like; OXA-4; VIM-2 | PDC-119-like | 233 |
13 | 1607996 | >32 | No lesion | WT | PDC-35; LCR-1; VIM-2; OXA-2 | PDC-35 | 2613 |
14 | 1652654 | >32 | Frameshift, 354 AA protein | WT | PDC-252-like; OXA-4; VIM-2 | PDC-252-like | 233 |
15 | 1652655 | >32 | Disrupted by insertion | WT | PDC-252-like; OXA-4; VIM-2 | PDC-252-like | 233 |
16 | 1652663 | >32 | Frameshift, 135 AA protein | WT | PDC-11; OXA-10; VEB-1 | PDC-11 | 357 |
17 | 1723966 | >32 | Frameshift, 135 AA protein | WT | PDC-11; OXA-10; VEB-1 | PDC-11 | 357 |
18 | 1724010 | >32 | Frameshift, 135 AA protein | WT | PDC-11; VEB-1; OXA-10 | PDC-11 | 357 |
19 | 1724024 | >32 | No lesion | WT | PDC-35; OXA-2; VIM-2; LCR-1 | PDC-35 | 2613 |
20 | 1724321 | >32 | Frameshift, 135 AA protein | WT | PDC-11; OXA-10; VEB-1 | PDC-11 | 357 |
21 | 1724327 | >32 | Frameshift, 135 AA protein | WT | PDC-11; OXA-10; VEB-1 | PDC-11 | 357 |
22 | 1734172 | 8 | E176STOP | WT | PDC-212-like | PDC-212-like | 272 |
23 | 1734205 | >32 | Disrupted by insertion | WT | PDC-252-like; OXA-4; VIM-2 | PDC-252-like | 233 |
24 | 1734215 | >32 | Frameshift, 354 AA protein | WT | PDC-119-like; OXA-4; VIM-2 | PDC-119-like | 233 |
25 | 1734223 | 16 | Q424STOP | WT | PDC-279-like | PDC-279-like | 244 |
Oman | |||||||
1 | 1688133 | >32 | Frameshift, 218 AA protein | L346M; F533L | PDC-98; OXA-10; OXA-1-like | PDC-98 | 664 |
2 | 1688134 | >32 | No lesion | WT | PDC-30 | PDC-30 | 207 |
AA, amino acid; C/T, ceftolozane/tazobactam.
Amino acid changes are greater relative to reference sequences.
Threshold for β-lactamase gene inclusion was 72% and 80% for minimum nucleotide sequence identity and minimum sequence length, respectively.
Novel MLSTs were given sequential designations for clarity.